Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., has sold a portion of its holdings in multiple transactions on February 15, 2024.

Summary

• Lilly Endowment Inc. sold a total of 50,316 shares of Eli Lilly & Co. common stock on February 15, 2024.
• The sales were executed in multiple transactions at weighted average prices of $760.191, $761.558, and $762.261 per share.
• The total number of shares owned by Lilly Endowment Inc. after these transactions is 99,068,494.
• The sales were conducted under a pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The document is a routine filing of a share sale by a major shareholder, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to a significant shareholder adjusting their position in the company. Such transactions are common and do not necessarily indicate a change in the company's prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The transactions are within the normal range of trading activity for a large institutional investor like Lilly Endowment Inc.
• Similar filings are regularly made by other large shareholders of comparable companies such as Pfizer, Johnson & Johnson, and Merck.

Stakeholder Impact

• The share sale may have a minor impact on the stock price in the short term, but is unlikely to have a significant long-term effect.
• The transaction does not directly impact employees, customers, or suppliers.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, Form 4